CanBas Co. Ltd.   Report issue

For profit Phase 2
Founded: Numazu Japan (2000)

Organization Overview

First Clinical Trial
2006
NCT00551512
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CanBas Co. Ltd.

Active Ingredients

Drugs in Phase 2 Trials (4)

cbp 501 (5 trials)

cisplatin (platinol) (4 trials)

nivolumab (opdivo) (1 trial)

pemetrexed (alimta) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Mesothelioma (Phase 2)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 4